

Doxorubicin Market Size Worth \$1.86 Billion by 2029 - Exclusive Report by The Business Research Company

*The Business Research Company's
Doxorubicin Global Market Report 2025 –
Market Size, Trends, And Global Forecast
2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, November 24, 2025
/EINPresswire.com/ -- How Much Is The
[Doxorubicin Market](#) Worth?

The Business
Research Company

The Business Research Company

The market size for doxorubicin has impressively increased in the past few years. It is expected to rise from a worth of \$1.33 billion in 2024 to approximately \$1.42 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%. The significant growth witnessed during the historical period owes to developments in chemotherapy, standardization of oncology treatment, clinical effectiveness, improvement in patient survival odds, and suggestions from physicians.



Get 20% Off All Global
Market Reports With Code
ONLINE20 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors

”

*The Business Research
Company*

The market for doxorubicin is anticipated to experience significant growth in the upcoming years, with forecasts projecting it reaching a worth of \$1.86 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.1%. The predicted growth during the forecast period is linked to advancements in personalized medicine, the development of targeted drug delivery systems, combinations of immunotherapy, research in genomics and biomarkers, and the expansion of precision oncology.

Key trends expected during the forecast period include the integration of nanotechnology, various combination therapies, the enlargement of the biosimilar market, a stronger focus on adjuvant therapy, and interventions to protect the heart.

Download a free sample of the doxorubicin market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=11974&type=smp>

What Are The Factors Driving The Doxorubicin Market?

The rising cases of cancer are propelling the growth of the doxorubicin market. Cancer consists of a variety of illnesses that cause cells to develop irregularly and uncontrollably. Doxorubicin, a typical antibiotic, is frequently used in chemotherapy to treat numerous forms of cancer by inhibiting cancer cell growth through DNA damage. The escalating rate of cancer has caused an increase in the demand for doxorubicin. For example, the World Health Organization, based in Switzerland, noted in February 2024 that there were about 20 million new cases of cancer and 9.7 million deaths due to the disease in 2022. It is estimated that 53.5 million individuals were alive five years after being diagnosed with cancer. Approximately 1 in 5 people will get cancer during their lifetime, with roughly 1 in 9 men and 1 in 12 women dying from the disease. As a result, the growing number of cancer patients is fueling the doxorubicin market.

Who Are The Major Players In The Doxorubicin Market?

Major players in the Doxorubicin include:

- Pfizer Inc.
- Johnson and Johnson
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cipla Limited
- Hikma Pharmaceuticals
- Mylan Pharmaceuticals Inc.
- Accord Healthcare Ltd.
- TTY Biopharm Company Limited

What Are The Key Trends And Market Opportunities In The Doxorubicin Sector?

Key players in the doxorubicin market are concentrating their efforts on producing next-generation products such as chemotherapy drugs that can enhance the success of cancer treatments while mitigating negative effects. These chemotherapy medications are designed to attack and destroy swiftly multiplying cancerous cells. Though they can affect some healthy cells and cause side effects, ongoing advancements are working towards increasing their specificity, thereby minimizing harm. For example, in August 2024, Lupin Limited, a pharmaceutical firm based in India, introduced Doxorubicin Hydrochloride Liposome Injection. This injection functions as a treatment for advanced ovarian cancer, AIDS-associated Kaposi's sarcoma, and multiple myeloma. It possesses a liposomal formulation, which allows for targeted drug delivery. This reduces the occurrence of widespread side effects while improving patient comfort and endurance. Such a strategy amplifies the effectiveness of the treatment, rendering it as an essential tool in cancer therapies.

Which Segment Accounted For The Largest Doxorubicin Market Share?

The doxorubicin market covered in this report is segmented –

- 1) By Drug Formulation: Lyophilized Powder, Doxorubicin Injection
- 2) By Application: Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, Other Applications
- 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

- 1) By Lyophilized Powder: Reconstituted Formulations, Freeze-Dried Preparations
- 2) By Doxorubicin Injection: Ready-To-Use Solutions, Concentrated Solutions For Dilution, Liposomal Doxorubicin Injections

View the full doxorubicin market report:

<https://www.thebusinessresearchcompany.com/report/doxorubicin-global-market-report>

What Are The Regional Trends In The Doxorubicin Market?

In 2024, North America dominated the Doxorubicin market. It is projected that Asia-Pacific will witness the most rapid growth in the upcoming forecast period. The report on the Doxorubicin market encompasses regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the [Global Doxorubicin Market 2025](#), [By The Business Research Company](#)

Chemicals Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/chemicals-global-market-report>

Chemicals By End Use Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/chemicals-by-end-use-global-market-report>

Ethyl Alcohol And Other Basic Organic Chemical Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/ethyl-alcohol-and-other-basic-organic-chemical-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
[LinkedIn](#)
[Facebook](#)
[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/869154199>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.